AstraZeneca
Assembly Line
Nucleus RadioPharma Secures Series A Extension Funding with AstraZeneca Investment
Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, announced the closing of a Series A extension round with new investor AstraZeneca (LSE/STO/Nasdaq: AZN). AstraZeneca joins existing investors from GE Healthcare, Mayo Clinic, Eclipse Ventures, Fox Chase Cancer Center, Echo Global Granger Management Mercy Health, and the University of Missouri as Nucleus expands development, supply, and commercial manufacturing capabilities to make targeted radiotherapies and theranostics more accessible to patients globally. Concurrent with the financing, Tyrell Rivers, PhD, Executive Director of Corporate Ventures at AstraZeneca, was named to the Board of Directors.